Diagnosis of PD by visualization of nigrosome 1: which imaging modality to use?

Given a misdiagnosis rate of approximately 20% in Parkinson’s disease (PD), especially at early stages, imaging biomarkers are needed to improve the accuracy of clinical diagnosis.

A research group at the Clínica Universidad de Navarra, Madrid, Spain, compared 3T susceptibility-weighted magnetic resonance imaging (SW-MRI) of the substantia nigra and striatal 18F‐DOPA positron emission tomography (PET) for visualizing the biomarker nigrosome 1 in two groups:

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.